Special Feature
PharmExec’s Brand of the Year: Merck's Januvia
Halfway through its patent lifecycle, Januvia has beaten expectations to become – along with Janumet, Januvia's fixed-dose metformin sibling – the best selling product franchise in Merck's history. In the increasingly crowded Type 2 diabetes therapeutic area, will Januvia continue to grow on its current success, or will the second half of its lifecycle suffer from pancreas-related side effects and new competition from SGLT2 inhibitors? ...Read more
Cegedim Relationship Management
Webinar: Successful Samples Management
Join us to hear current trends in sample management and reconciliations including insight to how others are meeting the challenges via presentation of key industry metrics. Also hear from your peers about the benefits of leveraging a third party for selected activities and learn key success factors when outsourcing aspects of your sample management.  Click Here To Register
North America
Are US and Candian Rx Policies Converging?
As the US pharmaceutical industry anxiously watches the rapid onset of Obamacare, certainly one of the more pressing issues is the debate over the number of drugs that will be reimbursed in each therapeutic class under the Essential Health Benefits (EHB) program. To say that this is a critical concern for the future of the US pharmaceutical industry would a gross understatement, writes Tom Norton ...Read More
Regulatory
OGD Head Quits, Generic Reorganization Plan Hits Trouble
After less than a year on the job, the Head of FDA’s Office of Generic Drugs (OGD) has announced his departure, a sign that all is not well with plans for major organizational changes at the Center for Drug Evaluation and Research (CDER) ...Read more
CEO Compensation Data
Complete salary, bonus & market capitalization data in biotech.
 www.bioworld.com
Adherence
Refilling the Antiobiotic Pipeline
With the US Center for Disease Control (CDC) and Britain’s Chief Medical Officer issuing separate warnings about the urgent problem of antibiotic resistance in infectious diseases, a discussion is needed around which incentives and regulatory mechanisms might work to catalyze development programs and rehydrate the pipeline for these increasingly vital medicines ...Read more
Engage Nurse Practitioners through their Trusted Destination: Generation NP Communicate. Collaborate. Educate
Live Webcast: Tuesday, March 26, 2013 from 11:00am–12:00pm ET
Register Free at: www.pharmexec.com/generationNP
Drug Safety
Congress, FDA Should Consider Tech Solutions for Safer Compounding
Last fall’s deadly meningitis outbreak linked to contaminated steroid injections is a tragic reminder of the risk of errors inherent in manual pharmacy medication compounding. Nearly 700 people fell ill in 19 states, and more than 40 died. Can technology prevent another outbreak, asks Niels Erik Hansen ...Read more
R&D
AstraZeneca's R&D Trimdown
AstraZeneca's decision to cut 1,600 jobs and shutter operations at its Alderly Park, UK facility reconfirms a trend and points to a shift in the way Big Pharma invents and develops new products. The Alderly Park closure aligns with new CEO Pascal Soriot’s push for more deal-making in an effort to replenish AstraZeneca's depleted drug portfolio ...Read more
|
